Scholarlink

<p>Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, restricted therapeutic options, and dismal prognosis. Conventional therapeutic modalities demonstrate limited efficacy, especially for unresectable or metastatic cases. Recent advancements in molecular profiling have revolutionized ATC management, facilitating the development of novel targeted therapies, immunotherapies, and multimodal regimens. Growing clinical evidence indicates these innovative approaches may enhance locoregional control, increase surgical candidacy in select patients, and extend overall survival. Incorporating molecular-guided therapies into multidisciplinary care is fundamentally transforming ATC management. Nevertheless, therapeutic resistance, intratumoral heterogeneity, and the paucity of large-scale prospective trials remain major obstacles. Future efforts should focus on optimizing combinatorial strategies and developing robust biomarker-driven algorithms to improve clinical outcomes in ATC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review

  • 期刊论文

  • 发表日期：

    2026年6月22日

查看全文
  • Juncong Fan,
  • Yeqin Ni,
  • Rong Ni,
  • Gang Pan,
  • You Peng,
  • Li Zhou,
  • Ruirui Jing,
  • Ping Song,
  • Dingcun Luo

摘要

Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy characterized by rapid progression, restricted therapeutic options, and dismal prognosis. Conventional therapeutic modalities demonstrate limited efficacy, especially for unresectable or metastatic cases. Recent advancements in molecular profiling have revolutionized ATC management, facilitating the development of novel targeted therapies, immunotherapies, and multimodal regimens. Growing clinical evidence indicates these innovative approaches may enhance locoregional control, increase surgical candidacy in select patients, and extend overall survival. Incorporating molecular-guided therapies into multidisciplinary care is fundamentally transforming ATC management. Nevertheless, therapeutic resistance, intratumoral heterogeneity, and the paucity of large-scale prospective trials remain major obstacles. Future efforts should focus on optimizing combinatorial strategies and developing robust biomarker-driven algorithms to improve clinical outcomes in ATC.